Stock TEVA TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Teva Pharmaceutical Industries Limited TEL AVIV STOCK EXCHANGE

Equities

TEVA

IL0006290147

Market Closed - TEL AVIV STOCK EXCHANGE
Other stock markets
 10:24:13 2024-07-11 am EDT 		5-day change 1st Jan Change
6,211 ILa +4.76% Intraday chart for Teva Pharmaceutical Industries Limited -1.04% +62.80%
Jul. 01 Sector Update: Health Care Stocks Retreat Late Afternoon MT
Jul. 01 Sector Update: Health Care Stocks Slipping in Afternoon Trading MT

Summary

  • The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

  • The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • The company has a low valuation given the cash flows generated by its activity.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • For several months, analysts have been revising their EPS estimates roughly upwards.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • Over the past four months, analysts' average price target has been revised upwards significantly.
  • Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses

  • As estimated by analysts, this group is among those businesses with the lowest growth prospects.
  • The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
  • The average consensus view of analysts covering the stock has deteriorated over the past four months.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
TEVA PHARMACEUTICAL INDUSTRIES LIMITED Stock Teva Pharmaceutical Industries Limited
+62.80% 19.37B -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+62.66% 841B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+40.42% 625B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.37% 360B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+17.16% 327B
B-
ABBVIE INC. Stock AbbVie Inc.
+9.87% 300B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+15.66% 242B
B+
NOVARTIS AG Stock Novartis AG
+17.90% 227B
B-
AMGEN INC. Stock Amgen Inc.
+14.86% 174B
C+
PFIZER, INC. Stock Pfizer, Inc.
+0.45% 162B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. TEVA Stock
  4. TEVA Stock
  5. Ratings Teva Pharmaceutical Industries Limited